




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 311/20, A61K 31/215	A1	(11) International Publication Number: WO 98/16506 (43) International Publication Date: 23 April 1998 (23.04.98)
(21) International Application Number: PCT/US97/18170 (22) International Filing Date: 8 October 1997 (08.10.97) (30) Priority Data: 08/729,359 16 October 1996 (16.10.96) US (71) Applicant: AMERICAN CYANAMID COMPANY [US/US]; Five Giralda Farms, Madison, NJ 07940-0974 (US). (72) Inventors: LEVIN, Jeremy, Ian; 190 Treetop Circle, Nanuet, NY 10954 (US). ZASK, Arie; 200 Central Park South, New York, NY 10019 (US). GU, Yansong; 82 North Magnolia Avenue, Pearl River, NY 10965 (US). (74) Agents: ALICE, Ronald, W.; American Home Products Cor- poration, One Campus Drive, Parsippany, NJ 07054 (US) et al.		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: BETA-SULFONAMIDO HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS (57) Abstract <p>The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-α converting enzyme (TACE, tumor necrosis factor-α converting enzyme) which are useful for the treatment of diseases in which these enzymes are implicated such as arthritis, tumor growth and metastasis, angiogenesis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, proteinuria, aneurysmal aortic disease, degenerative cartilage loss following traumatic joint injury, demyelinating diseases of the nervous system, graft rejection, cachexia, anorexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease, HIV infection, age related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, ocular inflammation, keratoconus, Sjogren's syndrome, myopia, ocular tumors, ocular angiogenesis/neovascularization. The TACE and MMP inhibiting ortho-sulfonamido aryl hydroxamic acids of the present invention are represented by formula (1) where the hydroxamic acid moiety and the sulfonamido moiety are bonded to adjacent carbons on group A where: A is a 5 to 7 membered, monocyclic, non-aromatic heterocyclic ring having from 1 to 2 heteroatoms independently selected from N, O, and S, optionally substituted by R¹, R², R³ and R⁴; a -C₃-C₇-cycloalkyl containing 0-2 double bonds and optionally substituted with R¹, R², R³ and R⁴; or -CHR⁵=CHR⁶-; and Z, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ are described in the specification, and the pharmaceutically acceptable salts thereof, and the optical isomers and diastereomers thereof.</p> <div style="text-align: right; margin-top: 20px;">  <p style="text-align: right;">(1)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

BETA-SULFONAMIDO HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS

5

Background of the Invention

The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF- α converting enzyme (TACE, tumor necrosis factor- α converting enzyme) which are useful for the treatment of diseases in which these enzymes are implicated such as arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, proteinuria, aneurysmal aortic disease, degenerative cartilage loss following traumatic joint injury, demyelinating diseases of the nervous system and HIV infection.

Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes [Woessner, J.F., Jr. *FASEB J.* 1991, 5, 2145; Birkedal-Hansen, H.; Moore, W.G.I.; Bodden, M.K.; Windsor, L.J.; Birkedal-Hansen, B.; DeCarlo, A.; Engler, J.A. *Crit. Rev. Oral Biol. Med.* 1993, 4, 197; Cawston, T.E. *Pharmacol. Ther.* 1996, 70, 163; Powell, W.C.; Matrisian, L.M. *Cur. Top. Microbiol. and Immunol.* 1996, 213, 1]. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. Of these classes, the gelatinases have been shown to be the MMPs most intimately involved with the growth and spread of tumors, while the collagenases have been associated with the pathogenesis of osteoarthritis [Howell, D.S.; Pelletier, J.-P. In *Arthritis and Allied Conditions*; McCarthy, D.J.; Koopman, W.J., Eds.; Lea and Febiger: Philadelphia, 1993; 12th Edition Vol. 2, pp. 1723; Dean, D.D. *Sem. Arthritis Rheum.* 1991, 20, 2; Crawford, H.C; Matrisian, L.M. *Invasion Metast.* 1994-95, 14, 234; Ray, J.M.; Stetler-Stevenson, W.G. *Exp. Opin. Invest. Drugs*, 1996, 5, 323].

It is known that the level of expression of gelatinase is elevated in malignancies, and that gelatinase can degrade the basement membrane which may lead to tumor metastasis [Powell, W.C.; Matrisian, L.M. *Cur. Top. Microbiol. and Immunol.* 1996, 213, 1; Crawford, H.C; Matrisian, L.M. *Invasion Metast.* 1994-95, 14, 234; Ray, J.M.; Stetler-Stevenson, W.G. *Exp. Opin. Invest. Drugs*, 1996, 5, 323; Himmelstein, B.P.; Canete-Soler, R.; Bernhard, E.J.; Dilks, D.W.; Muschel, R.J. *Invasion Metast.* 1994-95, 14, 246; Nuovo, G.J.; MacConnell, P.B.; Simsir, A.; Valea, F.; French, D.L. *Cancer Res.*

1995, 55, 267-275; Walther, M.M.; Levy, A.; Hurley, K.; Venzon, D.; Linehen, W.M.; Stetler-Stevenson, W. *J. Urol.* 1995, 153 (Suppl. 4), 403A; Tokuraku, M; Sato, H.; Murakami, S.; Okada, Y.; Watanabe, Y.; Seiki, M. *Int. J. Cancer*, 1995, 64, 355; Himelstein, B.; Hua, J.; Bernhard, E.; Muschel, R.J. *Proc. Am. Assoc. Cancer Res. Ann. Meet.* 1996, 37, 632; Ueda, Y.; Imai, K.; Tsuchiya, H.; Fujimoto, N.; Nakanishi, I.; Katsuda, S.; Seiki, M.; Okada, Y. *Am. J. Pathol.* 1996, 148, 611; Gress, T.M.; Mueller-Pillasch, F.; Lerch, M.M.; Friess, H.; Buechler, M.; Adler, G. *Int. J. Cancer*, 1995, 62, 407; Kawashima, A.; Nakanishi, I.; Tsuchiya, H.; Roessner, A.; Obata, K.; Okada, Y. *Virchows Arch.*, 1994, 424, 547-552.]. Angiogenesis, required for the growth of solid tumors, has also recently been shown to have a gelatinase component to its pathology [Crawford, H.C; Matrisian, L.M. *Invasion Metast.* 1994-95, 14, 234; Ray, J.M.; Stetler-Stevenson, W.G. *Exp. Opin. Invest. Drugs*, 1996, 5, 323.]. Furthermore, there is evidence to suggest that gelatinase is involved in plaque rupture associated with atherosclerosis [Dollery, C.M.; McEwan, J.R.; Henney, A.M. *Circ. Res.* 1995, 77, 863; Zempo, N.; Koyama, N.; Kenagy, R.D.; Lea, H.J.; Clowes, A.W. *Arterioscler. Thromb. Vasc. Biol.* 1996, 16, 28; Lee, R.T.; Schoen, F.J.; Loree, H.M.; Lark, M.W., Libby, P. *Arterioscler. Thromb. Vasc. Biol.* 1996, 16, 1070.]. Other conditions mediated by MMPs are restenosis, MMP-mediated osteopenias, inflammatory diseases of the central nervous system, skin aging, tumor growth, osteoarthritis, rheumatoid arthritis, septic arthritis, corneal ulceration, abnormal wound healing, bone disease, proteinuria, aneurysmal aortic disease, degenerative cartilage loss following traumatic joint injury, demyelinating diseases of the nervous system, cirrhosis of the liver, glomerular disease of the kidney, premature rupture of fetal membranes, inflammatory bowel disease, periodontal disease, age related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, ocular inflammation, keratoconus, Sjogren's syndrome, myopia, ocular tumors, ocular angiogenesis/neovascularization and corneal graft rejection.


The hypothesis that MMPs are important mediators of the tissue destruction that occurs in arthritis has long been considered, since it was first recognized that these enzymes are capable of degrading collagens and proteoglycans which are the major structural components of cartilage [Sapolsky, A.I.; Keiser, H.; Howell, D.S.; Woessner, J.F., Jr.; *J. Clin. Invest.* 1976, 58, 1030; Pelletier, J.-P.; Martel-Pelletier, J.; Howell, D.S.; Ghandur-Mnaymneh, L.; Enis, J.E.; Woessner, J.F., Jr., *Arthritis Rheum.* 1983, 26, 63.], and continues to develop as new MMPs are identified. For example, collagenase-3 (MMP-13) was cloned from breast cancer cells in 1994, and the first report that it could be involved in arthritis appeared in 1995 [Freiji, J.M.; Diez-Itza, I.; Balbin, M.; Sanchez, L.M.; Blasco, R.; Tolivia, J.; Lopez-Otin, C. *J. Biol. Chem.* 1994, 269, 16766; Flannery, C.R.; Sandy, J.D. 102-17, 41st Ann. Meet. Orth. Res. Soc. Orlando, FL.

February 13-16, 1995.]. Evidence is accumulating that implicates MMP-13 in the pathogenesis of arthritis. A major structural component of articular cartilage, type II collagen, is the preferred substrate for MMP-13 and this enzyme is significantly more efficient at cleaving type II collagen than the other collagenases [Knauper, V.; Lopez-Otin, C.; Smith, B.; Knight, G.; Murphy, G. *J. Biol. Chem.*, **1996**, *271*, 1544-1550; Mitchell, P.G.; Magna, H.A.; Reeves, L.M.; Lopresti-Morrow, L.L.; Yocum, S.A.; Rosner, P.J.; Geoghegan, K.F.; Hambor, J.E. *J. Clin. Invest.* **1996**, *97*, 761.]. MMP-13 is produced by chondrocytes, and elevated levels of MMP-13 has been found in human osteoarthritic tissues [Reboul, P.; Pelletier, J-P.; Hambor, J.; Magna, H.; Tardif, G.; Cloutier, J-M.; Martel-Pelletier, J. *Arthritis Rheum.* **1995**, *38 (Suppl. 9)*, S268; Shlopov, B.V.; Mainardi, C.L.; Hasty, K.A. *Arthritis Rheum.* **1995**, *38 (Suppl. 9)*, S313; Reboul, P.; Pelletier, J-P.; Tardif, G.; Cloutier, J-M.; Martel-Pelletier, J. *J. Clin. Invest.* **1996**, *97*, 2011]. Potent inhibitors of MMPs were described over 10 years ago, but the poor bioavailability of these early peptidic, substrate mimetic MMP inhibitors precluded their evaluation in animal models of arthritis. More bioavailable, non-peptidic MMP inhibitors may be preferred for the treatment of diseases mediated by MMPs.

TNF- α converting enzyme catalyzes the formation of TNF- α from membrane bound TNF- α precursor protein. TNF- α is a pro-inflammatory cytokine that is now thought to have a role in rheumatoid arthritis, septic shock, graft rejection, insulin resistance and HIV infection in addition to its well documented antitumor properties. For example, research with anti-TNF- α antibodies and transgenic animals has demonstrated that blocking the formation of TNF- α inhibits the progression of arthritis [Rankin, E.C.; Choy, E.H.; Kassimos, D.; Kingsley, G.H.; Sopwith, A.M.; Isenberg, D.A.; Panayi, G.S. *Br. J. Rheumatol.* **1995**, *34*, 334; *Pharmaprojects*, **1996**, Therapeutic Updates *17 (Oct.)*, au197-M2Z.]. This observation has recently been extended to humans as well. Other conditions mediated by TNF- α are congestive heart failure, cachexia, anorexia, inflammation, fever, inflammatory disease of the central nervous system, and inflammatory bowel disease.


It is expected that small molecule inhibitors of gelatinase and TACE therefore have the potential for treating a variety of disease states. While a variety of MMP and TACE inhibitors have been identified and disclosed in the literature, the vast majority of these molecules are peptidic or peptide-like compounds that may have bioavailability and pharmacokinetic problems that would limit their clinical effectiveness. Low molecular weight, potent, long-acting, orally bioavailable inhibitors of gelatinases, collagenases and/or TACE are therefore highly desirable for the potential chronic treatment of the above mentioned disease states. Several non-peptidic, sulfur-containing hydroxamic acids have recently been disclosed and are listed below.

U. S. patents 5,455,258, 5,506,242 and 5,552,419, as well as European patent application EP606,046A1 and WIPO international publications WO96/00214 and WO97/22587 disclose non-peptide matrix metalloproteinase inhibitors of which the compound CGS27023A is representative. The discovery of this type of MMP inhibitor is further detailed by MacPherson, *et. al.* in *J. Med. Chem.*, (1997), 40, 2525. Additional publications disclosing sulfonamide based MMP inhibitors which are variants of the sulfonamide-hydroxamate shown below, or the analogous sulfonamide-carboxylates, are European patent application EP-757984-A1 and WIPO international publications WO95/35275, WO95/35276, WO96/27583, WO97/19068 and WO97/27174.




CGS 27023A


Publications disclosing β -sulfonamide-hydroxamate MMP inhibitor analogs of CGS 27023A in which the carbon alpha to the hydroxamic acid has been joined in a ring to the sulfonamide nitrogen, as shown below, include WIPO international publications WO96/33172 and WO97/20824.



The German patent application DE19,542,189-A1 discloses additional examples of cyclic sulfonamides as MMP inhibitors. In this case the sulfonamide-containing ring is fused to a phenyl ring to form an isoquinoline.



5 Analogs of the sulfonamide-hydroxamate MMP inhibitors in which the sulfonamide nitrogen has been replaced by a carbon atom, as shown in the general structure below, are European patent application EP-780386-A1 and WIPO international publication WO97/24117.




10

Summary of the Invention

The TACE and MMP inhibiting β -sulfonamido hydroxamic acids of the present invention are represented by the formula

15



where the hydroxamic acid moiety and the sulfonamido moiety are bonded to adjacent carbons of group A where:

20

A is a 5 to 7 membered saturated or unsaturated monocyclic heterocyclic ring

having from 1 to 2 heteroatoms independently selected from N, O, and S, optionally substituted by R¹, R², R³ and R⁴;

a -C₃-C₇-cycloalkyl containing 0-2 double bonds and optionally substituted with R¹, R², R³ and R⁴;

25

or -CHR⁵=CHR⁶-;

Z is aryl, heteroaryl, or heteroaryl fused to a phenyl,

where aryl is phenyl or naphthyl optionally substituted by R¹, R², R³ and R⁴;

heteroaryl is a 5-6 membered heteroaromatic ring having from 1 to 3

5 heteroatoms independently selected from N, O, and S, and optionally substituted by R¹, R², R³ and R⁴;

and when heteroaryl is fused to phenyl, either or both of the rings can be optionally substituted by R¹, R², R³ and R⁴;

10 R¹, R², R³ and R⁴ are independently -H, -COR⁵, -F, -Br, -Cl, -I, -C(O)NR⁵OR⁶, -CN, -OR⁵, -C₁-C₄-perfluoroalkyl, -S(O)_xR⁵ where x is 0-2, -OPO(OR⁵)OR⁶, -PO(OR₆)R⁵, -OC(O)NR⁵R⁶, -COOR⁵, -CONR⁵R⁶, -SO₃H, -NR⁵R⁶, -NR⁵COR⁶, -NR⁵COOR⁶, -SO₂NR⁵R⁶, -NO₂, -N(R⁵)SO₂R⁶, -NR⁵CONR⁵R⁶,
15 -NR⁵C(=NR⁶)NR⁵R⁶, 3-6 membered cycloheteroalkyl having one to three heteroatoms independently selected from N, O, and S and optionally having 1 or 2 double bonds and optionally substituted by one to three groups each selected independently from R⁵; -aryl or heteroaryl as defined above, -SO₂NHCOR⁵ or -CONHSO₂R⁵ where R⁵ is not H;
20 -tetrazol-5-yl, -SO₂NHCN, -SO₂NHCONR⁵R⁶ or straight chain or branched -C₁-C₆ alkyl, -C₂-C₆-alkenyl, or -C₂-C₆-alkynyl, or -C₃-C₆-cycloalkyl optionally having 1 or 2 double bonds each optionally substituted with -COR⁵, -CN, -C₂-C₆ alkenyl, -C₂-C₆ alkynyl, -OR⁵, -C₁-C₄-perfluoroalkyl, -S(O)_xR⁵ where x is 0-2, -OC(O)NR⁵R⁶, -COOR⁵,
25 -CONR⁵R⁶, -SO₃H, -NR⁵R⁶, -NR⁵COR⁶, -NR⁵COOR⁶, -SO₂NR⁵R⁶, -NO₂, -N(R⁵)SO₂R⁶, -NR⁵CONR⁵R⁶, -C₃-C₆ cycloalkyl as defined above, 3-6 membered cycloheteroalkyl as defined above, aryl or heteroaryl as defined above, -SO₂NHCOR⁵ or -CONHSO₂R⁵ where R⁵ is not hydrogen, -PO(OR⁵)OR⁶, -PO(OR⁶)R⁵, -tetrazol-5-yl, -C(O)NR⁵OR⁶, -NR⁵C(=NR⁶)NR⁵R⁶, -SO₂NHCONR⁵R⁶ or -SO₂NHCN;

30 with the proviso that when R¹ and R² are on adjacent carbons of A, R¹ and R² together with the carbons to which they are attached can form a 5-7 membered saturated or unsaturated monocyclic heterocyclic ring, or a 5-6
35 membered heteroaryl ring, each having from 1 to 2 heteroatoms independently selected from N, O, and S, wherein said heterocyclic or heteroaryl ring may be optionally substituted by one to four groups each

selected independently from R⁴; or R¹ and R² together with the carbons to which they are attached can form a 5-7 membered saturated or unsaturated carbocyclic ring or an aryl ring wherein said carbocyclic or aryl ring may be optionally substituted by one to four groups each selected independently from R⁴;

R⁵ and R⁶ are independently defined as H, aryl and heteroaryl as defined above, -C₃-C₆-cycloalkyl as defined above, -C₃-C₆-cycloheteroalkyl as defined above, -C₁-C₄-perfluoroalkyl, or straight chain or branched -C₁-C₆ alkyl, -C₂-C₆-alkenyl, or -C₂-C₆-alkynyl each optionally substituted with -OH, -COR⁸, -CN, -C(O)NR⁸OR⁹, -C₂-C₆-alkenyl, -C₂-C₆-alkynyl, -OR⁸, -C₁-C₄-perfluoroalkyl, -S(O)_xR⁸ where x is 0-2, -OPO(OR⁸)OR⁹, -PO(OR⁸)R⁹, -OC(O)NR⁸R⁹, -COOR⁸, -CONR⁸R⁹, -SO₃H, -NR⁸R⁹, -NCOR⁸R⁹, -NR⁸COOR⁹, -SO₂NR⁸R⁹, -NO₂, -N(R⁸)SO₂R⁹, -NR⁸CONR⁸R⁹, -C₃-C₆ cycloalkyl as defined above, -C₃-C₆- cycloheteroalkyl as defined above, -aryl or heteroaryl as defined above, -SO₂NHCOR⁸ or -CONHSO₂R⁸ where R⁸ is not hydrogen, -tetrazol-5-yl, -NR⁸C(=NR⁹)NR⁸R⁹, -SO₂NHCONR⁸R⁹, -SO₂NHCN;

R⁷ is hydrogen, straight chain or branched -C₁-C₆-alkyl, -C₂-C₆-alkenyl, or -C₂-C₆-alkynyl each optionally substituted with -OH, -COR⁵, -CN, -C₂-C₆-alkenyl, -C₂-C₆-alkynyl, -OR⁵, -C₁-C₄-perfluoroalkyl, -S(O)_xR⁵ where x is 0-2, -OPO(OR⁵)OR⁶, -PO(OR⁵)R⁶, -OC(O)NR⁵R⁶, -COOR⁵, -CONR⁵R⁶, -SO₃H, -NR⁵R⁶, -NR⁵COOR⁶, -NR⁵COOR⁶, SO₂NR⁵R⁶, -NO₂, -N(R⁵)SO₂R⁶, -NR⁵CONR⁵R⁶, -C₃-C₆ cycloalkyl as defined above, -C₃-C₆-cycloheteroalkyl as defined above, -aryl or heteroaryl as defined above, -SO₂NHCOR⁵ or -CONHSO₂R⁵ where R⁵ is not hydrogen, -tetrazol-5-yl, -NR⁵C(=NR⁶)NR⁵R⁶, -C(O)NR⁵OR⁶, -SO₂NHCONR⁵R⁶ or -SO₂NHCN;

or R⁷ is phenyl or naphthyl, optionally substituted by R¹, R², R³ and R⁴ or a 5 to 6 membered heteroaryl group having 1 to 3 heteroatoms selected independently from N, O, and S and optionally substituted by R¹, R², R³ and R⁴;

or R⁷ is C₃-C₆ cycloalkyl or 3-6 membered cycloheteroalkyl as defined above;











5 or R⁷CH₂-N-A-, where A is as defined above, can form with the carbon adjacent to the carbon bearing the sulfonamido group, a non-aromatic fused 7-10 membered heterocyclic ring optionally containing an additional heteroatom selected from O, S and N wherein said heterocyclic ring may be optionally fused to another benzene ring;

10 R⁸ and R⁹ are independently H, aryl or heteroaryl as defined above, -C₃-C₇-cycloalkyl or cycloheteroalkyl as defined above, -C₁-C₄-perfluoroalkyl, straight chain or branched -C₁-C₆-alkyl, -C₂-C₆-alkenyl, or -C₂-C₆-alkynyl, each optionally substituted with hydroxy, alkoxy, aryloxy, -C₁-C₄-perfluoroalkyl, amino, mono- and di-C₁-C₆-alkylamino, carboxylic
15 acid, carboalkoxy and carboaryloxy, nitro, cyano, carboxamido primary, mono- and di-C₁-C₆-alkylcarbonyl;

and the pharmaceutically acceptable salts thereof and the optical isomers and distereomers thereof.

20 The term "5-7 membered saturated or unsaturated monocyclic heterocyclic ring having from 1 to 2 heteroatoms independently selected from N, O, and S" as defined hereinabove includes, but is not limited to, tetrahydrofuran, tetrahydrothiophene, tetramethylene sulfone, tetrahydropyran, dihydropyran, pyrrolidine, morpholine and piperidine. The term "5 to 6 membered heteroaryl" as defined hereinabove includes, but is
25 not limited to, pyrrole, furan, thiophene, pyridine, pyrimidine, pyridazine, pyrazine, triazole, pyrazole, imidazole, isothiazole, thiazole, isoxazole and oxazole. The term "heteroaryl fused to a phenyl" includes, but is not limited to, indole, isoindole, benzofuran, benzothiophene, quinoline, isoquinoline, quinoxaline, quinazoline, benzotriazole, indazole, benzimidazole, benzothiazole, benzisoxazole, and benzoxazole.

30 The following compounds (I-X) which may be used in preparing compounds of the invention are known and references are given hereinbelow.

**I****II****III****IV****V****VI****VII****VIII****IX****X****Compounds I and II:**

Jacobsen, Poul; Schaumburg, Kjeld; Krogsgaard-Larsen, Povl. **Acta Chem. Scand., Ser. B** (1980), B34(5), 319-26.

Compound III:

a) Baldwin, Jack E.; Adlington, Robert M.; Gollins, David W.; Godfrey, Christopher R. A. **Tetrahedron** (1995), 51(17), 5169-80.

b) Gallina, C.; Marta, C.; Colombo, C.; Romeo, A. **Tetrahedron** (1971), 27(19), 4681-5.

c) Kogoori, Yasushi; Wakayama, Mikio; Sano, Tetsuya; Sato, Yuji. **Jpn. Kokai Tokyo Koho**, JP 04360866 A2 .

d) Gallina, Carlo; Koch, Virginio; Romeo, Aurelio. **Tetrahedron Lett.** (1969), (35), 3055-6.

Compound IV:

- a) Thorbek, Pia; Hjeds, Hans; Schaumburg, Kjeld. **Acta Chem. Scand., Ser. B** (1981), B35(7), 473-9.
- b) Kunisch, Franz; Mittendorf, Joachim; Plempel, Manfred; Militzer, Hans
5 Christian. **Eur. Pat. Appl.**, EP 538692 A1.

Compound V:

- a) Kunisch, Franz; Mittendorf, Joachim; Plempel, Manfred. **Eur. Pat. Appl.**, EP 538688 A1.
- b) Crowley, Patrick Jelf; Heaney, Stephen Paul; Lawson, Kevin Robert; Youle,
10 David. **PCT Int. Appl.**, WO 9507022 A1.

Compound VI:

- a) Mittendorf, Joachim; Kunisch, Franz; Plempel, Manfred. **Eur. Pat. Appl.**, EP 538691 A1.
- b) Crowley, Patrick Jelf; Heaney, Stephen Paul; Lawson, Kevin Robert; Youle,
15 David. **PCT Int. Appl.**, WO 9507022 A1.

Compound VII:

Mittendorf, Joachim; Kunisch, Franz; Plempel, Manfred. **Eur. Pat. Appl.**, EP 538691 A1.

Compound VIII:

- 20 Kunisch, Franz; Mittendorf, Joachim; Plempel, Manfred. **Eur. Pat. Appl.**, EP 538688 A1.

Compound IX:

Malis, Jerry L.; Rosenthale, Marvin E. US Patent 3746495.

Compound X:


- 25 Ohki, Hidenori; Inamoto, Yoshiko; Kawabata, Kohji; Kamimura, Toshiaki; Sakane, Kazuo. **J. Antibiot.** (1991), 44(5), 546-9.

30 The compounds of this invention are shown to inhibit the enzymes MMP-1, MMP-9, MMP-13 and TNF- α converting enzyme (TACE) and are therefore useful in the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, graft rejection, insulin resistance, bone disease and HIV infection.

Detailed description of the Invention


The following reaction scheme (Scheme I) shows the general reaction route followed for the synthesis of hydroxamic acids of this invention. For purposes of illustration only, trans-2-aminocyclohexane carboxylic acid, wherein A is represented by a cyclohexyl ring, is sulfonated with p-methoxybenzene sulfonamide, wherein Z is p-methoxybenzene, to provide a sulfonamide which is first converted into its t-butyl ester and then alkylated with benzyl bromide, wherein R⁷ is benzyl, to give the N,N-disubstituted sulfonamide which is subsequently converted into the corresponding hydroxamic acid in two steps.

Scheme I.




Schemes II and III illustrate two methods for incorporating amino groups into the substituent attached to the sulfonamide nitrogen of the compounds of the invention. Thus, in Scheme II the NH-sulfonamide is alkylated with propargyl bromide to provide the propargyl sulfonamide. This alkyne is reacted with paraformaldehyde in the presence of a primary or secondary amine and cuprous chloride to give the propargyl amine which is converted, as before, to the desired hydroxamic acid.

Scheme II.




In Scheme III, selective hydrolysis of the ester of the p-carboethoxybenzyl sulfonamide group provides a mono-carboxylic acid. This acid may be converted into an amide (not shown), followed by conversion of the ester A-CO₂R into the corresponding hydroxamate, or reduced to the corresponding alcohol with diborane. The alcohol may be converted into the analogous amine via the benzylic bromide, followed by conversion of the ester A-CO₂R into the corresponding hydroxamate.

10 Scheme III.




Methods for synthesizing variations of substituents on the sulfonyl aryl group are shown in Schemes IV through VI. As shown in Scheme IV, biaryl sulfonyl groups are synthesized by Suzuki couplings on a bromo-substituted benzene sulfonamide. The starting bromo-substituted benzene sulfonamide is synthesized from the commercially available bromobenzenesulfonyl chloride and the amino-acid or amino-ester, $H_2N-A-CO_2R$, followed by alkylation of the resulting NH-sulfonamide. Alternatively, the bromo aryl sulfonamide is converted into the corresponding boronic acid by the method of Ishiyama, et.al. [J. Org. Chem. (1995), 60, 7508] followed by coupling with an appropriate aryl halide.

Scheme IV.




Methods for synthesizing sulfonyl aryl ethers are shown in Schemes V through VII. In Scheme V biaryl ethers, or aryl heteroaryl ethers, are synthesized starting from the known sulfonyl chlorides (see for example: Zook SE; Dagnino, R; Deason, ME, Bender, SL; Melnick, MJ WO 97/20824).

Scheme V.




Alternatively, the biaryl ethers may be prepared from the corresponding boronic acids or via the sulfonyl phenols as shown in Scheme VI.

Scheme VI.




Aryl ethers may also be prepared via displacement of the fluorine from a para-fluorobenzene sulfonamide, as shown in Scheme VII. Aryl or alkyl ethers may be prepared in this manner.

5 Scheme VII.



Starting materials for other groups, A, of the invention are synthetically accessible. For example, the piperidine analogs shown in Scheme VIII should be readily available from the analogous pyridines via hydrogenation.

Scheme VIII.



Basic salts of the hydroxamic acids can be formed with pharmaceutically acceptable alkali-forming metal cations such as lithium, sodium, potassium, calcium and aluminum. Acid addition salts can be formed when a substituent contains a basic amino group using a pharmaceutically acceptable inorganic or organic acid such as hydrochloric, hydrobromic, phosphoric, sulfuric, acetic, benzoic, succinic, lactic, malic, maleic, fumaric or methanesulfonic acids.

The following specific examples are included for illustrative purposes and are not to be construed as limiting to this disclosure in any way. Other procedures useful for the preparation of compounds of this invention will be apparent to those skilled in the art.

Example 1

(trans)-2-(4-Methoxybenzenesulfonyl)aminocyclohexanecarboxylic acid

To a room temperature solution of 1g (6.8 mmol) of trans-2-amino-1-cyclohexylcarboxylic acid in 50 ml of dioxane:H₂O (1:1) containing 1.7 ml (12.2 mmol) of triethylamine was added 1.54g (7.46 mmol) of 4-methoxybenzenesulfonyl chloride. The mixture was stirred at 25 °C for 18 h. The resulting mixture was diluted with pentane to afford 1.119 g (51%) of the desired sulfonamide product as a white solid. ¹H NMR(DMSO-d₆): 7.7 ppm (dd, 2H, Ar), 7.4 ppm (d, 1H, NH), 7.0 ppm (dd, 2H, Ar), 3.8 ppm (s, 3H, OMe), 3.5 ppm (m, 1H, N-CH), 1.0-1.7 ppm (m, 9H, hydrocarbon).

Example 2

(cis)-2-(4-Methoxybenzenesulfonyl)aminocyclohexanecarboxylic acid

In the same manner as described in Example 1, 2.5 g (17 mmol) of cis-2-amino-1-cyclohexylcarboxylic acid provided 3.283 g (60%) of the desired carboxylic acid. Electrospray Mass Spec 314.1 (M+H).

Example 3

(trans)-2-(4-Methoxybenzenesulfonyl)aminocyclohexanecarboxylic acid t-butyl ester

To a solution of 0.313g (1 mmol) of the product from Example 1 in 5.0 mL of toluene was added 1 mL (4 mmol) of N,N-dimethylformamide di-tert-butyl acetal. The resulting mixture was heated at 110 °C for 4h under nitrogen and then allowed to cool to room temperature. The solution was then poured on top of a silica gel column. Chromatography on silica gel eluting with 10-20% ethyl acetate/hexane gave 353 mg (96%) of the desired ester as a white solid. ¹H NMR(CDCl₃): 7.8 ppm (dd, 2H, Ar), 7.0 ppm (dd, 2H, Ar), 5.7 ppm (d, 1H, NH), 3.9 ppm (s, 3H, OMe), 3.4 ppm (m, 1H, N-CH), 2.5 ppm (m, 1H, CH-CO₂-), 1.0-2.0 ppm (m, 17H, hydrocarbon).

Example 4

(cis)-2-(4-Methoxy-benzenesulfonylamino)-cyclohexanecarboxylic acid tert-butyl ester

In the same manner as described in Example 3, 1.438 g (4.59 mmol) of the product from Example 2 provided 0.739 g (44%) of the desired tert-butyl ester as a colorless oil. Electrospray Mass Spec 370.1 (M+H).

Example 5

(trans)-2-[Benzyl-(4-methoxybenzenesulfonyl)amino]-cyclohexanecarboxylic acid t-butyl ester

To a solution of 1.146 g (3.1 mmol) of the product from Example 3 in 31 mL of DMF was added 0.137g (3.42 mmol) of 60% sodium hydride. The resulting mixture was stirred for 30 min at 25°C and then 0.42 mL (3.50 mmol) of benzyl bromide was added all at once. This reaction mixture was stirred for 10 hr at 55 °C and then poured into water and extracted with ether. The combined organics were washed with water and brine, dried over MgSO₄, filtered and concentrated in vacuo to provide a white solid which was recrystallized from EtOAc/Hexanes to provide 1.364 g (95%) of the desired product. ¹H NMR(CDCl₃): 7.7 ppm (dd, 2H, Ar), 7.1-7.4 (m, 5H, Ar), 6.9 ppm (dd, 2H, Ar), 4.5-4.7 ppm (AB quartet, 2H, CH₂-Ar), 3.9 ppm (s, 3H, OMe), 4.0 ppm (m, 1H, N-CH), 2.9 ppm (m, 1H, CH-CO₂-), 1.0-2.3 ppm (m, 17H, hydrocarbon protons).

Example 6

(cis)-2-[Benzyl-(4-methoxy-benzenesulfonyl)-amino]-cyclohexanecarboxylic acid tert-butyl ester

In the same manner as described in Example 5, 0.600 g (1.62 mmol) of the product

from Example 4 provided 0.310 g (42%) of the desired benzylated ester as a colorless oil. Electrospray Mass Spec 460.1 (M+H).

Example 7

**(trans)-2-[Benzyl-(4-methoxy-benzenesulfonyl)-amino]-
cyclohexanecarboxylic acid**

To a solution of 1.364 g (2.97 mmol) of the product from Example 5 in 10mL of dichloromethane was added 10mL of trifluoroacetic acid and the mixture was stirred for 4h at room temperature. The solvent was then concentrated in vacuo and the residue was chromatographed on silica gel eluting with 10-100% ethyl acetate/hexane to provide 1.092 g (73%) of the desired product as a white solid. Electrospray Mass Spec 404.2 (M+H)

Example 8

**(cis)-2-[Benzyl-(4-methoxy-benzenesulfonyl)-amino]-
cyclohexanecarboxylic acid**

In the same manner as described in Example 7, 0.240 g (0.522 mmol) of the product from Example 6 provided 0.207 g (98%) of the desired carboxylic acid as a white solid. Electrospray Mass Spec 404.0 (M-H).

Example 9

**(trans)-2-[Benzyl-(4-methoxy-benzenesulfonyl)-amino]-
cyclohexanecarboxylic acid hydroxyamide**

To a solution of 807 mg (2 mmol) of the product from Example 7 in 20 mL of dichloromethane was added 0.05 mL of DMF followed by 2.2 mL (2.52 mmol) of a 2 M solution of oxalyl chloride and the resulting reaction mixture was stirred at room temperature for 0.5 h.

In a separate flask, 4 mL (29 mmol) of triethylamine was added to a 0 °C mixture of 695 mg (10 mmol) of hydroxylamine hydrochloride in 22 mL of THF and 5 mL of water. After this mixture had been stirred for 15min at 0 °C, the acid chloride solution was added to it in one portion and the resulting solution was allowed to warm to room temperature and stirred for another 4h. Water was then added to the reaction flask and 854 mg (100% yield) of the desired hydroxamic acid was collected via filtration as a white solid. Electrospray Mass Spec 419.3 (M+H)

Example 10

**(cis)-2-[Benzyl-(4-methoxy-benzenesulfonyl)-amino]-
cyclohexanecarboxylic acid hydroxyamide**

In the same manner as described in Example 9, 0.144 g (0.357 mmol) of the product from
5 Example 8 provided 0.90 g (60%) of the desired carboxylic acid as a white solid.
Electrospray Mass Spec 419.1 (M+H).

Pharmacology10 **Procedures for Measuring MMP-1, MMP-9, and MMP-13 Inhibition**

These assays are based on the cleavage of a thiopeptide substrates such as Ac-Pro-
Leu-Gly(2-mercapto-4-methyl-pentanoyl)-Leu-Gly-OEt by the matrix metalloproteinases
MMP-1, MMP-13 (collagenases) or MMP-9 (gelatinase), which results in the release of a
15 substrate product that reacts colorimetrically with DTNB (5,5'-dithiobis(2-nitro-benzoic
acid)). The enzyme activity is measured by the rate of the color increase. The thiopeptide
substrate is made up fresh as a 20 mM stock in 100% DMSO and the DTNB is dissolved in
100% DMSO as a 100 mM stock and stored in the dark at room temperature. Both the
20 substrate and DTNB are diluted together to 1 mM with substrate buffer (50 mM HEPES
pH 7.5, 5 mM CaCl₂) before use. The stock of enzyme is diluted with assay buffer (50
mM HEPES, pH 7.5, 5 mM CaCl₂, 0.02% Brij) to the desired final concentration. The
assay buffer, enzyme, vehicle or inhibitor, and DTNB/substrate are added in this order to a
96 well plate (total reaction volume of 200 μ l) and the increase in color is monitored
spectrophotometrically for 5 minutes at 405 nm on a plate reader and the increase in color
25 over time is plotted as a linear line.

Alternatively, a fluorescent peptide substrate is used. In this assay, the peptide
substrate contains a fluorescent group and a quenching group. Upon cleavage of the
substrate by an MMP, the fluorescence that is generated is quantitated on the fluorescence
plate reader. The assay is run in HCBC assay buffer (50mM HEPES, pH 7.0, 5 mM
30 Ca⁺², 0.02% Brij, 0.5% Cysteine), with human recombinant MMP-1, MMP-9, or MMP-
13. The substrate is dissolved in methanol and stored frozen in 1 mM aliquots. For the
assay, substrate and enzymes are diluted in HCBC buffer to the desired concentrations.
Compounds are added to the 96 well plate containing enzyme and the reaction is started by
the addition of substrate. The reaction is read (excitation 340 nm, emission 444 nm) for 10
35 min. and the increase in fluorescence over time is plotted as a linear line.

For either the thiopeptide or fluorescent peptide assays, the slope of the line is
calculated and represents the reaction rate. The linearity of the reaction rate is confirmed (r^2
>0.85). The mean ($x \pm \text{sem}$) of the control rate is calculated and compared for statistical
significance ($p < 0.05$) with drug-treated rates using Dunnett's multiple comparison test.

Dose-response relationships can be generated using multiple doses of drug and IC₅₀ values with 95% CI are estimated using linear regression.

Procedure for Measuring TACE Inhibition

5

Using 96-well black microtiter plates, each well receives a solution composed of 10 μ L TACE (Immunex, final concentration 1 μ g/mL), 70 μ L Tris buffer, pH 7.4 containing 10% glycerol (final concentration 10 mM), and 10 μ L of test compound solution in DMSO (final concentration 1 μ M, DMSO concentration <1%) and incubated for 10 minutes at room temperature. The reaction is initiated by addition of a fluorescent peptidyl substrate (final concentration 100 μ M) to each well and then shaking on a shaker for 5 sec.

10

The reaction is read (excitation 340 nm, emission 420 nm) for 10 min. and the increase in fluorescence over time is plotted as a linear line. The slope of the line is calculated and represents the reaction rate.

15

The linearity of the reaction rate is confirmed ($r^2 > 0.85$). The mean ($x \pm \text{sem}$) of the control rate is calculated and compared for statistical significance ($p < 0.05$) with drug-treated rates using Dunnett's multiple comparison test. Dose-response relationships can be generate using multiple doses of drug and IC₅₀ values with 95% CI are estimated using linear regression.

20

Results of the above in-vitro matrix metalloproteinase inhibition and TACE inhibition pharmacological assays are given in Table I below.

Table I. Inhibition of MMP and TACE

Example	MMP-1 ¹	MMP-9 ¹	MMP-13 ¹	TACE ¹
9	176	181	233	1612
10	616	275	286	24%

25

1. IC₅₀ nM or % inhibition at 1 μ M concentration

Pharmaceutical Composition

Compounds of this invention may be administered neat or with a pharmaceutical carrier to a patient in need thereof. The pharmaceutical carrier may be solid or liquid.

30

Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size

35

desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.

5 Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs. The active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives,
10 sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above, e.g., cellulose derivatives, preferable sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) and their
15 derivatives, and oils (e.g., fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.

 Liquid pharmaceutical compositions which are sterile solutions or suspensions can
20 be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be either liquid or solid composition form.

 The compounds of this invention may be administered rectally in the form of a conventional suppository. For administration by intranasal or intrabronchial inhalation or
25 insufflation, the compounds of this invention may be formulated into an aqueous or partially aqueous solution, which can then be utilized in the form of an aerosol. The compounds of this invention may also be administered transdermally through the use of a transdermal patch containing the active compound and a carrier that is inert to the active compound, is non-toxic to the skin, and allows delivery of the agent for systemic
30 absorption into the blood stream via the skin. The carrier may take any number of forms such as creams and ointments, pastes, gels, and occlusive devices. The creams and ointments may be viscous liquid or semi-solid emulsions of either the oil in water or water in oil type. Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the active ingredient may also be suitable. A variety of occlusive
35 devices may be used to release the active ingredient into the blood stream such as a semipermeable membrane covering a reservoir containing the active ingredient with or

without a carrier, or a matrix containing the active ingredient. Other occlusive devices are known in the literature.

The dosage to be used in the treatment of a specific patient suffering a MMP or TACE dependent condition must be subjectively determined by the attending physician.

5 The variables involved include the severity of the dysfunction, and the size, age, and response pattern of the patient. Treatment will generally be initiated with small dosages less than the optimum dose of the compound. Thereafter the dosage is increased until the optimum effect under the circumstances is reached. Precise dosages for oral, parenteral, nasal, or intrabronchial administration will be determined by the administering physician


10 based on experience with the individual subject treated and standard medical principles.

Preferably the pharmaceutical composition is in unit dosage form, e.g., as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage form can be packaged compositions, for example packed powders, vials, ampoules, prefilled syringes or sachets containing liquids.

15 The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.

What is claimed:

1. A compound having the formula:



where the hydroxamic acid moiety and the sulfonamido moiety are bonded to adjacent carbons of group A where:

A is a 5 to 7 membered, monocyclic, non-aromatic heterocyclic ring having from 1 to 2 heteroatoms independently selected from N, O, and S, optionally substituted by R¹, R², R³ and R⁴;

a -C₃-C₇-cycloalkyl containing 0-2 double bonds and optionally substituted with R¹, R², R³ and R⁴;

or -CHR⁵=CHR⁶-;

Z is aryl, heteroaryl, or heteroaryl fused to a phenyl,

where aryl is phenyl or naphthyl optionally substituted by R¹, R², R³ and R⁴;

heteroaryl is a 5-6 membered heteroaromatic ring having from 1 to 3 heteroatoms independently selected from N, O, and S, and optionally substituted by R¹, R², R³ and R⁴;

and when heteroaryl is fused to phenyl, either or both of the rings can be optionally substituted by R¹, R², R³ and R⁴;

R¹, R², R³ and R⁴ are independently -H, -COR⁵, -F, -Br, -Cl, -I, -C(O)NR⁵OR⁶, -CN, -OR⁵, -C₁-C₄-perfluoroalkyl, -S(O)_xR⁵ where x is 0-2, -OPO(OR⁵)OR⁶, -PO(OR⁶)R⁵, -OC(O)NR⁵R⁶, -COOR⁵, -CONR⁵R⁶, -SO₃H, -NR⁵R⁶, -NR⁵COR⁶, -NR⁵COOR⁶, -SO₂NR⁵R⁶, -NO₂, -N(R⁵)SO₂R⁶, -NR⁵CONR⁵R⁶, -NR⁵C(=NR⁶)NR⁵R⁶, -C₃-C₆-cycloalkyl optionally having 1 or 2 double bonds and optionally substituted with one to three groups each selected independently from R⁵, 3-6 membered cycloheteroalkyl having one to four heteroatoms independently selected from N, O, and S, optionally having 1 or 2 double bonds

and optionally substituted by one to three groups each selected independently from R^5 ; -aryl or heteroaryl as defined above, -SO₂NHCOR⁵ or -CONHSO₂R⁵ where R^5 is not H, -tetrazol-5-yl, -SO₂NHCN, -SO₂NHCONR⁵R⁶ or straight chain or branched -C₁-C₆ alkyl, -C₂-C₆-alkenyl, or -C₂-C₆-alkynyl each optionally substituted with -COR⁵, -CN, -C₂-C₆ alkenyl, -C₂-C₆ alkynyl, -OR⁵, -C₁-C₄-perfluoroalkyl, -S(O)_xR⁵ where x is 0-2, -OC(O)NR⁵R⁶, -COOR⁵, -CONR⁵R⁶, -SO₃H, -NR⁵R⁶, -NR⁵COR⁶, -NR⁵COOR⁶, -SO₂NR⁵R⁶, -NO₂, -N(R⁵)SO₂R⁶, -NR⁵CONR⁵R⁶, -C₃-C₆ cycloalkyl as defined above, 3-6 membered cycloheteroalkyl as defined above, aryl or heteroaryl as defined above, -SO₂NHCOR⁵ or -CONHSO₂R⁵ where R^5 is not hydrogen, -PO(OR⁵)OR⁶, -PO(OR⁶)R⁵, -tetrazol-5-yl, -C(O)NR⁵OR⁶, -NR⁵C(=NR⁶)NR⁵R⁶, -SO₂NHCONR⁵R⁶ or -SO₂NHCN;

with the proviso that when R^1 and R^2 are on adjacent carbons of A, R^1 and R^2 together with the carbons to which they are attached can form a 5-7 membered saturated or unsaturated monocyclic heterocyclic ring, or a 5-6 membered heteroaryl ring, each having from 1 to 2 heteroatoms independently selected from N, O, and S, wherein said heterocyclic or heteroaryl ring may be optionally substituted by one to four groups each selected independently from R^4 ; or R^1 and R^2 together with the carbons to which they are attached can form a 5-7 membered saturated or unsaturated carbocyclic ring or an aryl ring wherein said carbocyclic or aryl ring may be optionally substituted by one to four groups each selected independently from R^4 ;

R^5 and R^6 are independently defined as H, aryl and heteroaryl as defined above, -C₃-C₆-cycloalkyl as defined above, -C₃-C₆-cycloheteroalkyl as defined above, -C₁-C₄-perfluoroalkyl, or straight chain or branched -C₁-C₆ alkyl, -C₂-C₆-alkenyl, or -C₂-C₆-alkynyl each optionally substituted with -OH, -COR⁸, -CN, -C(O)NR⁸OR⁹, -C₂-C₆-alkenyl, -C₂-C₆-alkynyl, -OR⁸, -C₁-C₄-perfluoroalkyl, -S(O)_xR⁸ where x is 0-2, -OPO(OR⁸)OR⁹, -PO(OR⁸)R⁹, -OC(O)NR⁸R⁹, -COOR⁸, -CONR⁸R⁹, -SO₃H, -NR⁸R⁹, -NCOR⁸R⁹, -NR⁸COOR⁹, -SO₂NR⁸R⁹, -NO₂, -N(R⁸)SO₂R⁹, -NR⁸CONR⁸R⁹, -C₃-C₆ cycloalkyl as defined above, -C₃-C₆-cycloheteroalkyl as defined

above, -aryl or heteroaryl as defined above, -SO₂NHCOR⁸ or
 -CONHSO₂R⁸ where R⁸ is not hydrogen, -tetrazol-5-yl,
 -NR⁸C(=NR⁹)NR⁸R⁹, -SO₂NHCONR⁸R⁹, -SO₂NHCN;

- 5 R⁷ is hydrogen, straight chain or branched -C₁-C₆-alkyl, -C₂-C₆-alkenyl, or -C₂-
 C₆-alkynyl each optionally substituted with -OH, -COR⁵, -CN, -C₂-C₆-
 alkenyl, -C₂-C₆-alkynyl, -OR⁵, -C₁-C₄-perfluoroalkyl, -S(O)_xR⁵
 where x is 0-2, -OPO(OR⁵)OR⁶, -PO(OR⁵)R⁶, -OC(O)NR⁵R⁶, -
 COOR⁵, -CONR⁵R⁶, -SO₃H, -NR⁵R⁶, -NR⁵COR⁶, -NR⁵COOR⁶,
 10 - SO₂NR⁵R⁶, -NO₂, -N(R⁵)SO₂R⁶, -NR⁵CONR⁵R⁶, -C₃-C₆
 cycloalkyl as defined above, -C₃-C₆-cycloheteroalkyl as defined
 above, -aryl or heteroaryl as defined above, -SO₂NHCOR⁵ or -
 CONHSO₂R⁵ where R⁵ is not hydrogen, -tetrazol-5-yl, -
 NR⁵C(=NR⁶)NR⁵R⁶, -C(O)N R⁵OR⁶, -SO₂NHCONR⁵R⁶ or -
 15 SO₂NHCN;
 or R⁷ is phenyl or naphthyl, optionally substituted by R¹, R², R³ and R⁴ or
 a 5 to 6 membered heteroaryl group having 1 to 3 heteroatoms
 selected independently from N, O, and S and optionally substituted
 by R¹, R², R³ and R⁴;
 20 or R⁷ is C₃-C₆ cycloalkyl or 3-6 membered cycloheteroalkyl as defined
 above;

or R⁷CH₂-N-A-, where A is as defined above, can form with the carbon adjacent to
 the carbon bearing the sulfonamido group, a non-aromatic fused 7-10
 25 membered heterocyclic ring optionally containing an additional
 heteroatomselected from O, S and N wherein said heterocyclic ring may be
 optionally fused to another benzene ring;

30 R⁸ and R⁹ are independently H, aryl or heteroaryl as defined above, -C₃-C₇-
 cycloalkyl or cycloheteroalkyl as defined above, -C₁-C₄-perfluoroalkyl,
 straight chain or branched -C₁-C₆-alkyl, -C₂-C₆-alkenyl, or -C₂-C₆-
 alkynyl, each optionally substituted with hydroxy, alkoxy, aryloxy, -C₁-
 C₄-perfluoroalkyl, amino, mono- and di-C₁-C₆-alkylamino, carboxylic
 acid, carboalkoxy and carboaryloxy, nitro, cyano, carboxamido primary,
 35 mono- and di-C₁-C₆-alkylcarbonyl;

an optical isomer or diastereomer thereof;
or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein the Z group is para-alkoxyphenyl, para-aryloxyphenyl or para-heteroaryloxyphenyl.

3. A compound according to claim 2 which is selected from the group consisting of:

(trans)-2-[Benzyl-(4-methoxy-benzenesulfonyl)-amino]-cyclohexanecarboxylic acid hydroxyamide, and

(cis)-2-[Benzyl-(4-methoxy-benzenesulfonyl)-amino]-cyclohexanecarboxylic acid hydroxyamide.

4. A method of inhibiting pathological changes mediated by matrix metalloproteinases in mammals which comprises administration to a mammal in need thereof a therapeutically effective amount of a matrix metalloproteinase inhibiting compound according to claim 1.

5. A method according to claim 4 wherein the condition treated is atherosclerosis, atherosclerotic plaque formation, reduction of coronary thrombosis from atherosclerotic plaque rupture, restenosis, MMP-mediated osteopenias, inflammatory diseases of the central nervous system, skin aging, angiogenesis, tumor metastasis, tumor growth, osteoarthritis, rheumatoid arthritis, septic arthritis, corneal ulceration, abnormal wound healing, bone disease, proteinuria, aneurysmal aortic disease, degenerative cartilage loss following traumatic joint injury, demyelinating diseases of the nervous system, cirrhosis of the liver, glomerular disease of the kidney, premature rupture of fetal membranes, inflammatory bowel disease, or periodontal disease.

6. A method according to claim 4 wherein the condition treated is age related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, ocular inflammation, keratoconus, Sjogren's syndrome, myopia, ocular tumors, ocular angiogenesis/neovascularization and corneal graft rejection.

7. A method of inhibiting pathological changes mediated by TNF- α converting enzyme (TACE) in mammals which comprises administration to a mammal in need thereof a therapeutically effective amount of a TACE inhibiting compound according to claim 1.

8. The method according to claim 7 wherein the condition treated is rheumatoid arthritis, graft rejection, cachexia, anorexia, inflammation, fever, insulin resistance, septic shock,

congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease, or HIV infection.

- 5 9. A pharmaceutical composition comprising a pharmaceutical carrier and a therapeutically effective amount of a matrix metalloproteinase or TACE inhibiting compound according to claim 1.

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C311/20 A61K31/215

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 22309 A (GLYCOMED INCORPORATED) 13 October 1994 * claim 1; claim 6, formula (2) *	1,9
A	EP 0 606 046 A (CIBA-GEIGY AG) 13 July 1994 cited in the application see claims	1,9
A	WO 96 29313 A (THE PROCTER & GAMBLE COMPANY) 26 September 1996 cited in the application see page 2-3	1,9

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

25 February 1998

Date of mailing of the international search report

05.03.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van Bijlen, H

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/ 18170

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 4-8
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 4-8
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9422309 A	13-10-94	AU 6554294 A CA 2160139 A EP 0692931 A JP 8511509 T	24-10-94 13-10-94 24-01-96 03-12-96
EP 606046 A	13-07-94	US 5455258 A AT 159012 T AU 684255 B AU 5265593 A CA 2112779 A DE 69314456 D FI 940012 A HU 70536 A JP 6256293 A MX 9400276 A NO 940038 A,B, NZ 250517 A US 5506242 A US 5552419 A US 5646167 A US 5672615 A ZA 9400048 A	03-10-95 15-10-97 11-12-97 04-05-95 07-07-94 13-11-97 07-07-94 30-10-95 13-09-94 29-07-94 07-07-94 26-10-95 09-04-96 03-09-96 08-07-97 30-09-97 11-08-94
WO 9629313 A	26-09-96	US 5672598 A AU 5255896 A CA 2216129 A EP 0815084 A NO 974335 A	30-09-97 08-10-96 26-09-96 07-01-98 21-11-97